Xpovio, a treatment for multiple myeloma, succeeded in entering the benefit one after another overseas. Expectations are growing that the registration of overseas lists will have a positive effect on Korea, given that there has been no country to refer to drug prices.

According to the pharmaceutical industry on the 25th, Canadian health authorities recently decided to reimburse for Antigen Pharmaceutical's new drug Xpovio, a multiple myeloma drug. Prior to this, it passed in Australia in March. Canada and Australia are not included in the A7 countries (US, UK, Germany, France, Italy, Switzerland, and Japan), which are drug reference countries. However, the domestic outlook is also bright as two countri